Edwards Lifesciences Corporation — News

Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.

benzinga.com - 2026-07-24 11:48:15

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

zacks.com - 2026-07-24 09:56:37

Total Sales: $1.74 billion, a 12.5% increase year-over-year.Adjusted EPS: $0.78 for the quarter.TAVR Sales: $1.3 billion, a 10.5% increase over the prior year.

gurufocus.com - 2026-07-24 00:00:00

Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-23 20:30:32

Edwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.

marketbeat.com - 2026-07-23 19:06:41

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-07-23 19:00:55

Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped ​by strong demand for its artificial heart ‌valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.

reuters.com - 2026-07-23 17:39:18

The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.

wsj.com - 2026-07-23 17:17:00

Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.

investors.com - 2026-07-23 16:36:13

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas.

businesswire.com - 2026-07-23 16:15:00

Andra AP fonden boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE: EW) by 283.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,969 shares of the medical research company's stock after acquiring an additional 84,969

defenseworld.net - 2026-07-22 03:51:11

EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.

zacks.com - 2026-07-20 10:25:24

Boston Common Asset Management LLC increased its holdings in shares of Edwards Lifesciences Corporation (NYSE: EW) by 4.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,297 shares of the medical research company's stock after purchasing an additional 6,744 shares during the

defenseworld.net - 2026-07-20 04:37:09

Diversify Wealth Management LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE: EW) by 91.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,910 shares of the medical research company's stock after selling 42,906 shares

defenseworld.net - 2026-07-19 04:11:20

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.About Edwards LifesciencesE.

businesswire.com - 2026-07-16 07:05:00

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com - 2026-07-03 12:34:00

NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.

businesswire.com - 2026-06-26 10:15:00

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, deterministic, and high-performance networking for modern Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, Reconnaissance (C5ISR), Electronic Warfare (EW), and edge computing applications. Aligned with SOSA™, CMOSS, and OpenVPX™ standards, the 3U VPX module combines advanced La.

businesswire.com - 2026-06-22 07:01:00

On June 17, 2026, we present a DCF analysis for Edwards Lifesciences Corp (EW). The company has shown a price performance of +1.2% over the past week, +8.8% ove

gurufocus.com - 2026-06-17 07:27:00

On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis.

benzinga.com - 2026-06-16 13:52:47

Edwards gains from strong TMTT growth, RESILIA adoption and expanding TAVR use, but macro pressures and currency swings remain key risks.

zacks.com - 2026-06-12 09:36:14

Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - East West Minerals Ltd. (TSXV: EW) ("East West" or the "Company") announces that further to a price reservation filed on June 10, 2026, the Company has arranged a non-brokered private placement financing (the "Financing") of up to 7,800,000 units (each a "Unit"), at a price of $0.11 per Unit, to raise up to $858,000.

newsfilecorp.com - 2026-06-12 08:00:00

On May 22, 2026, Edwards Lifesciences Corp (EW) shares rose 3.1% to a current price of $85.78. The stock has fluctuated between $72.30 and $87.89 over the past

gurufocus.com - 2026-05-22 17:20:00

On May 13, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown varied price performance recently. The stock has ex

gurufocus.com - 2026-05-13 08:15:00

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 20:30:44

On May 11, 2026, Edwards Lifesciences Corp (EW) shares fell 3.5%, bringing the current price to $77.17. The stock has experienced a 52-week range of $72.30 to $

gurufocus.com - 2026-05-11 19:45:00

Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.

youtube.com - 2026-05-10 14:30:53

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.

businesswire.com - 2026-05-04 16:45:00

CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv.

businesswire.com - 2026-05-02 11:50:00

During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.

seekingalpha.com - 2026-04-29 11:13:00

On April 29, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. Over the past w

gurufocus.com - 2026-04-29 07:30:00

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.

businesswire.com - 2026-04-28 07:05:00